Myeloma Paper of the Day, May 31st, suggested by Robert Orlowski
Robert Orlowski shared on X:
“Myeloma Paper of the Day: Phase II trial of Dara-KRd in newly diagnosed myeloma w/o transplant finds estimated 3-year PFS of 85%, OS of 95%, good agreement in MRD between NGS and EXENT automated mass spectrometry.”
Source: Robert Orlowski/X
Authors: Benjamin Derman, Jennifer Cooperrider, Jacalyn Rosenblatt, David Avigan, Murtuza Rampurwala, David Barnidge, Ajay Major, Theodore Karrison, Ken Jiang, Aubrianna Ramsland, Tadeusz Kubicki, and Andrzej Jakubowiak.
Other posts featuring Robert Orlowski on OncoDaily.
Robert Orlowski holds multiple positions at The University of Texas MD Anderson Cancer Center, including Chairman, Ad Interim Director of Myeloma, and Professor of Medicine in the Departments of Lymphoma/Myeloma and Experimental Therapeutics within the Division of Cancer Medicine.
Additionally, he chairs the SWOG Barlogie/Salmon Myeloma Committee, which is part of the National Clinical Trials Network, dedicated to advancing new therapies and understanding the biology of myeloma.
